Marguerite Koutsoukos

GlaxoSmithKline (Belgium) — Belgium

Immunology and Microbiology · Life Sciences

28h-index3.8kcitations68works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(35), SARS-CoV-2 and COVID-19 Research(20), vaccines and immunoinformatics approaches(15), Immune Cell Function and Interaction(13), Animal Virus Infections Studies(11)

Publications66 total

Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, nonrandomized extension of a phase 1/2 trial
International Journal of Infectious Diseases·2025· 1 citedOpen Access
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Frontiers in Immunology·2025· 2 citedOpen Access
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial
PLOS Global Public Health·2024Open Access
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
JAIDS Journal of Acquired Immune Deficiency Syndromes·2024· 5 citedOpen Access
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
PLoS Medicine·2024· 8 citedOpen Access
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120
The Journal of Infectious Diseases·2023· 6 citedOpen Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
The Lancet Respiratory Medicine·2023· 23 citedOpen Access
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
EClinicalMedicine·2023· 11 citedOpen Access
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
EClinicalMedicine·2023· 23 citedOpen Access
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
Communications Medicine·2023· 2 citedOpen Access
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates
Nature Communications·2023· 16 citedOpen Access
Beta variant COVID-19 protein booster vaccines elicit durable cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
2022Open Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
2022· 15 citedOpen Access
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
2022· 6 citedOpen Access
A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamsters
2022· 1 citedOpen Access
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
Frontiers in Immunology·2022· 3 citedOpen Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
The Journal of Infectious Diseases·2022· 47 citedOpen Access
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Nature Communications·2022· 46 citedOpen Access
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
2022· 7 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Gérald Voss(15), Patricia Bourguignon(12), Lawrence Corey(11), Carlos A. DiazGranados(11), Nicole Grunenberg(10), M. Juliana McElrath(10), Roman M. Chicz(10), James G. Kublin(9), Georgia D. Tomaras(9), Peter B. Gilbert(8), Clarisse Lorin(8), Matthew Bonaparte(8), Roger Masotti(8), Stephen J. Savarino(8), Lode Schuerman(8), Sanjay Gurunathan(8), Geert Leroux‐Roels(7), Nelson L. Michael(7), François Roman(7), Maria Angeles Ceregido(7)